Navidea Biopharmaceuticals and Macrophage Therapeutics to Host Post-International KSHV Conference Summary Webcast / Call
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) and its subsidiary, Macrophage Therapeutics, Inc., will hold a post-International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents conference webcast to provide investors with a more detailed look at the recently presented Manocept™ platform clinical and pre-clinical data and results disclosed in today’s press releases. The webcast will take place on July 7, 2015 at 1:00 pm EDT. Rick Gonzalez, Navidea’s CEO and Michael Goldberg, M.D., Macrophage Therapeutics’ CEO will host the call along with Michael S. McGrath, M.D., Ph.D., Professor, Departments of Laboratory Medicine, Pathology, and Medicine at the University of California, San Francisco who will discuss the data presented.
CONFERENCE CALL DETAILS
Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, http://ir.navidea.com, two to four hours after the live event.
|Event:||Macrophage Therapeutics KSHV Results Conference Call|
|Date/Time:||Tuesday, July 7, 2015 at 1:00 p.m. EDT|
|Live Dial-in Number – US:||1 (877) 407-0789|
|Live Dial in Number – Int’l:||
1 (201) 689-8562
Replay Dial-in Number –
|1 (877) 870-5176|
Replay Dial-in Number –
|1 (858) 384-5517|
|Replay PIN Number:||13613882|
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.
About Macrophage Therapeutics
Macrophage Therapeutics, Inc., a newly created subsidiary of Navidea Biopharmaceuticals, Inc. (NAVB), is developing therapeutics using the patented Manocept immunotherapy platform licensed from Navidea to target over-active macrophages implicated in cancer, cardiovascular, central nervous system, autoimmune, antiviral, and skin diseases. Manocept specifically targets CD206, or the mannose receptor prevalent on over-active macrophages. The technology enables highly specific targeted delivery of active (either existing or yet to be developed) agents that can modulate the activity of over-active macrophages that have been implicated in many diseases. Targeted delivery should significantly enhance a given compound’s efficacy and safety.
James Goldschmidt, Ph.D., 484-225-0341
Source: Navidea Biopharmaceuticals, Inc.
Released July 7, 2015